TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02582034

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Optimized Internal Radiation Therapy
Description: Injection of yttrium-90 microspheres (TheraSphere®) is performed during the therapeutic angiogram, directly into the hepatic artery (left or right, or even segmental).~Optimized dosimetry arm: the activity to be administered is calculated so as to deliver predictive dosimetry:~* An absorbed dose to the tumor of at least ≥ 205 Gy and if possible exceeding 250 Gy or even 300 Gy~* A dose at the treated healthy liver \< 120 Gy in case of lobar treatment~* Dose to the treated healthy liver can exceed 120 Gy in case of segmental treatment and hepatic reserve \> 30%~* A pulmonary dose \< 30 Gy for one treatment and \< 50 Gy in cumulative dose in case of multiple treatments.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard Internal Radiation Therapy
Description: Injection of yttrium-90 microspheres (TheraSphere®) is performed during the therapeutic angiogram, directly into the hepatic artery (left or right, or even segmental).Standard dosimetry arm: the activity to be administered is calculated so as predictive dosimetry:~* An absorbed dose of 120 ± 20 Gy to the treated volume (whatever the tumor absorbed dose)~* A pulmonary dose \< 30 Gy for one treatment and \< 50 Gy in cumulative dose in case of multiple treatments.
Study: NCT04854902

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Free gingival graft
Description: 1.5-2 x 5 x 10 mm size epithelialized graft harvested from the palate is stabilized in the mandibular anterior single-tooth recession region

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free gingival graft
Description: 1.5-2 x 5 x 10 mm size epithelialized graft harvested from the palate is stabilized in the mandibular anterior single-tooth recession region

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate
Description: N-Butyl-Cyanoacryle is applied to stabilize the graft to the recipient bed and to coat the donor site wound

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture
Description: The graft is stabilized with 6/0 polyvinylidene fluoride suture to the recipient bed
Study: NCT03560414

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: simple plasma exchange
Description: simple plasma exchange treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional PDF treatment group
Description: conventional PDF treatment group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: less plasma PDF treatment group
Description: less plasma Plasma diafiltration treatment
Study: NCT01574014

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBGT
Description: Cognitive-behavioral group therapy

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: CBGT
Description: Cognitive-behavioral group therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: 3 x 20 mg Hydrocortisone (oral, 60 min. before MRI1, 60 min. before exposition in CBGT1 and 60 min. before exposition in CBGT2)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (oral, 60 min. before MRI1, 60 min. before exposition in CBGT1 and 60 min. before exposition in CBGT2)
Study: NCT00136175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study: NCT01006447

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Instructor contact

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Instructor contact
Study: NCT03795402

Intervention type: DEVICE
Intervention: Microneedle Device
Description: Microneedle device will be used for collecting skin samples as a non-invasive method.

Intervention type: DEVICE
Intervention: Microneedle Device
Description: Microneedle device will be used for collecting skin samples as a non-invasive method.
Study: NCT02383927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: FTase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: FTase inhibitor
Study: NCT02453516

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus Block
Description: Ultrasound-guided nerve block using ropivacaine 0.5% (0.4ml/kg) injected between the serratus anterior and external intercostal muscles

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Block
Description: Subcutaneous injection of 1ml sterile normal saline solution in the midaxillary line

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: Drug indicated for regional anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinephrine
Description: Drug indicated to prolong the action of regional anesthesia

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sterile saline
Description: Neutral injection (no drug involved)
Study: NCT01121185

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MBL-HCV1
Description: 50 mg/kg MBL-HCV1, intravenous

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium chloride Placebo
Description: 0.9% sodium chloride, intravenous
Study: NCT01431105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin dose titration to maximum tolerated dose (once daily for 6 weeks)
Study: NCT01133925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resolute Sprint
Description: Zotarolimus Eluting Stent (Resolute Sprint) implanted in overlap

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus Eluting Stent
Description: Cypher stents implanted in overlap

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel Eluting Stent
Description: Taxus stents implanted in overlap

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zotarolimus eluting stent
Description: Endeavor stents implanted in overlap
Study: NCT03246399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04690
Description: suspension formulation of SM04690, delivered via intradiscal injection (single injection)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04690
Description: suspension formulation of SM04690, delivered via intradiscal injection (single injection)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04690
Description: suspension formulation of SM04690, delivered via intradiscal injection (single injection)
Study: NCT03397316

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: xenograft placement .
Description: immediate implant placement in upper esthetic zone with xenograft placement between residual labial bone and implant surface.
Study: NCT00402636

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rapamycin plus 17beta estradiolvalerat-eluting stent
Description: rapamycin plus 17beta estradiolvalerat-eluting stent was implanted due to randomisation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rapamycin-eluting stent
Description: rapamycin-eluting stent was implanted due to randomisation
Study: NCT02618863

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cricoid pressure
Description: Applying cricoid pressure and testing its effectiveness using gastric tube . in addition , by using the cricometer , the CP 50 is defined and compared in both gender

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cricoid pressure
Description: Applying cricoid pressure and testing its effectiveness using gastric tube . in addition , by using the cricometer , the CP 50 is defined and compared in both gender
Study: NCT02928809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-level laser therapy
Description: Three points will be irradiated over the masseter muscle (upper, middle and lower bundles) and one point will be irradiated over the anterior temporal muscle of each side of the face in the groups submitted to pre-fatigue laser. The following parameters will be employed: wavelength: 780 nm; energy density: 25 J/cm2; output power: 50 mW; power density: 1.25 W/cm2; and exposure time: 20 seconds per points, resulting in a total energy of 1 J per point. The laser will be applied punctually with a conventional tip in contact with the skin considering an area of 0.04 cm2.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-level laser therapy
Description: Three points will be irradiated over the masseter muscle (upper, middle and lower bundles) and one point will be irradiated over the anterior temporal muscle of each side of the face in the groups submitted to pre-fatigue laser. The following parameters will be employed: wavelength: 780 nm; energy density: 25 J/cm2; output power: 50 mW; power density: 1.25 W/cm2; and exposure time: 20 seconds per points, resulting in a total energy of 1 J per point. The laser will be applied punctually with a conventional tip in contact with the skin considering an area of 0.04 cm2.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: The same equipment will be used in the placebo group, but with a pen that emits a red guide light and a warning sound, but without the emission of a laser beam.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: The same equipment will be used in the placebo group, but with a pen that emits a red guide light and a warning sound, but without the emission of a laser beam.
Study: NCT03427008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth Intervention
Description: The mHealth app will allow transplant recipients to see their medication regimen, record themselves taking every dose, report side effects or symptoms, visualize their treatment progress, access educational content, and track appointments. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
Study: NCT01849913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser
Description: The laser will be used 830 nm, 30 milliwatts twice a week: the initial dosage will be 5.9 J per point. The irradiation will be performed bilaterally on the belly of the trapezius muscle as well as 2 cm to the right and left and 2 and 4 cm below the belly of the muscle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: To provide the blinding: the laser equipment has two identical application points furnished by the manufacturer - one active and the other a placebo (does not emit energy).
Study: NCT03477825

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Group A: Placebo group (n = 10)~* Supplement appearing similar to Herbal formulations~* Each placebo tablet will contain microcrystalline cellulose, dicalcium phosphate, PVPK30, sodium starch glycolate, magnesium stearate, OpaDry orange coating.~* Dose: subjects in this group will take 4 placebo tablets per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rubia Cordifolia
Description: Group B: R. cordifolia group (n = 10)~* 2,000 mg R. cordifolia per day - supplied by Banyan Botanicals and following standard supplementation doses on commercially available supplement (https://www.banyanbotanicals.com/manjistha-tablets/)~* Each tablet contains 500 mg of R. cordifolia per tablet.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Triphala
Description: Group C: Triphala group (n= 10)~* Tablets of Triphala will be supplied from Banyan Botanicals (https://www.banyanbotanicals.com/triphala-tablets-11/)~* Each tablet contains mix Emblica officinalis, Terminalia bellerica, and Terminalia chebula~* Dose: subjects will take 4 tablets per day, with a total dose of 2,000 mg of total herb.
Study: NCT01091519

Intervention type: OTHER
Intervention: Toviaz(fesoterodine) plus educational materials
Description: Educational materials including the Self-Assessment Goal Achievement (SAGA) tool to support dialogue.

Intervention type: OTHER
Intervention: Toviaz(fesoterodine) without educational materials
Description: No educational materials
Study: NCT02647645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Direct current stimulation at a current of 1.5 mA with anode at F3 (left dorsolateral prefrontal cortex) and cathode at Fp2 (right frontal pole) for a period of 20 minutes each for 6 sessions over two weeks simultaneously with cognitive training.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: Computer delivered intervention designed to improve cognitive speed and executive functioning for a period of 20 minutes each for 6 sessions over two weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Computer delivered intervention designed to improve cognitive speed and executive functioning for a period of 20 minutes each for 6 sessions over two weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Description: Direct current stimulation at a current of 1.5 mA with anode at F3 (left dorsolateral prefrontal cortex) and cathode at Fp2 (right frontal pole) for a period of one minute to simulate active treatment applied in 6 sessions over two weeks.
Study: NCT03524768

Intervention type: DIAGNOSTIC_TEST
Intervention: skin laser speckle contrast imaging and video-capillaroscopy
Description: Evaluation of endothelial-dependent microvascular reactivity and capillary recruitment

Intervention type: DIAGNOSTIC_TEST
Intervention: skin laser speckle contrast imaging and video-capillaroscopy
Description: Evaluation of endothelial-dependent microvascular reactivity and capillary recruitment
Study: NCT00097669

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo
Description: multivitamin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05646966

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: one time testing
Study: NCT03146871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant EphB4-HSA Fusion Protein
Description: Given IV
Study: NCT04666844

Intervention type: OTHER
Intervention: no intervention
Description: Observational Study
Study: NCT01920256

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote, personalized type 2 diabetes care.
Description: Diabetes and comorbidities will be managed with 1 clinic visit per year and frequent adjustments made remotely.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Endocrine care.
Description: Diabetes and comorbidities management will provided by an endocrinologist
Study: NCT01859962

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPI-668

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPI-668

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPI-668

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 207127 Dose 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 207127 Dose 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 207127 Dose 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Faldaprevir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Faldaprevir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Faldaprevir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 207127 Placebo
Study: NCT02258269

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: SQ

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SQ

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Study: NCT04414189

Intervention type: DIAGNOSTIC_TEST
Intervention: HostDx Sepsis
Description: Blood collection for mRNA analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: HostDx Sepsis
Description: Blood collection for mRNA analysis
Study: NCT00865267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultravate® 0.05% ointment, single exposure
Description: A: Experimental Subjects received Bristol-Myers Squibb Company formulated products
Study: NCT01254721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine fumarate
Description: eXtended Release(XR) 50mg, 200mg, 300mg and/or 400mg tablet, oral, once daily in the evening, from assignment to the end of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine fumarate
Description: eXtended Release(XR) 50mg, 200mg, 300mg and/or 400mg tablet, oral, once daily in the evening, from assignment to the end of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lithium
Description: 300mg tablet, oral
Study: NCT04438499

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eSense 7fr Single Sensor Bladder Catheter
Description: Urinary and abdominal catheters inserted in to the body to measure pressure for urodynamics.
Study: NCT00746317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC33
Description: IV administration at 4 escalating dose levels.
Study: NCT03319186

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EDIT Management
Description: EDIT management~1. Volumetric Pleural MRI for pre-aspiration pleural cavity volume~2. Large volume pleural aspiration with recording of intra-pleural pressure during aspiration~3. Volumetric Pleural MRI for post-aspiration pleural cavity volume~4. Computation of PEL250, defined as the rolling average of pleural elastance over the preceding 250ml aspirated.~   MaxPEL250 ≥ 14.5 cm H2O/L: allocated to 1st-line IPC MaxPEL250 \< 14.5 cm H2O/L: allocated to 1st-line TP~5. EDIT-directed 1st-line treatment to be delivered within 24 hours; if insufficient residual pleural fluid to allow standard Seldinger insertion technique then Boutin-type needle used for pneumothorax induction and guide wire insertion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chest drain and talc pleurodesis
Description: Intercostal chest drain insertion and talc slurry instillation according to British Thoracic Society guidelines
Study: NCT03918538

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home rehabilitation exercise program
Description: After pre-test, the intervention participants received a 60 minutes of teaching regarding the home rehabilitation exercise program, with a printed exercise manual. The intervention participants also received a weekly phone call from the interventionist to enhance their exercise adherence and helping to overcome exercise barriers.
Study: NCT02442856

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thigh Cuff
Study: NCT02134522

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP).
Description: Continuous positive airway pressure is a commonly prescribed therapy for obstructive sleep apnea which is recommended for the treatment of obstructive sleep apnea in children and adults.
Study: NCT01361126

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Coagulation Factor IX Albumin Fusion Protein
Description: Study subjects will receive a single dose of 25IU/kg of rIX_FP for pharmacokinetic analysis. Subjects will then be treated for approximately 5 months. The treatment dose will be based on the subject's PK profile and the subject's bleeding phenotype.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Coagulation Factor IX Albumin Fusion Protein
Description: Study subjects will receive a single dose of 25IU/kg of rIX_FP for pharmacokinetic analysis. Subjects will then be treated for approximately 5 months. The treatment dose will be based on the subject's PK profile and the subject's bleeding phenotype.
Study: NCT01930461

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SLIT tablets of HDM allergen extracts, 3 different doses (A)
Description: Two sublingual tablets daily for 13 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SLIT tablets of HDM allergen extracts, 3 different doses (B)
Description: Two sublingual tablets daily for 13 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SLIT tablets of HDM allergen extracts, 3 different doses (C)
Description: Two sublingual tablets daily for 13 months

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching the SLIT tablets of HDM allergen extracts
Description: Two sublingual tablets daily for 13 months
Study: NCT01540032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low salicylate diet
Description: Patients will avoid foods from the 'high salicylate' group completely. They can eat foods from the 'low salicylate' group freely and just eat foods from the medium group occasionally, and not in large amounts.

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Normal diet
Description: Patients will eat their usual diet.
Study: NCT04627376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal education and support program for cancer related cachexia prevention
Description: 12-weeks multimodal program includes: 4 meetings (with cancer nurse and clinical dietician). In this 4 meetings (about 30 minutes) they will have blood tests (CRP, Albumin levels), body composition measurements, questionnaires, education on their diet and symptom management related to anti cancer treatment.
Study: NCT01701284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Study: NCT03937466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling mattress pad
Description: The cooling mattress pad is a commercially available pad designed to be placed between the top of a mattress and bed sheets. It allows for precise temperature regulation in one's bed.
Study: NCT02236533

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: whole grain pasta
Description: Volunteers were fed with probiotic fortified pasta or control pasta once a day for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whole grain pasta
Description: Volunteers were fed with probiotic fortified pasta or control pasta once a day for 12 weeks.